Lombardi Comprehensive Cancer Center and Department of Oncology, School of Medicine, Georgetown University, Washington, District of Columbia, United States of America.
PLoS One. 2010 Jan 6;5(1):e8604. doi: 10.1371/journal.pone.0008604.
BCL2 family members affect cell fate decisions in breast cancer but the role of BCL-W (BCL2L2) is unknown. We now show the integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI; Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer variants; MCF-7/LCC1 (ICI sensitive), MCF-7/LCC9 (ICI resistant), and LY2 (ICI resistant). YC137 inhibits BCL-W and BCL2 and restores ICI sensitivity in resistant cells. Co-inhibition of BCL-W and BCL2 is both necessary and sufficient to restore sensitivity to ICI, and explains mechanistically the action of YC137. These data implicate functional cooperation and/or redundancy in signaling between BCL-W and BCL2, and suggest that broad BCL2 family member inhibitors will have greater therapeutic value than targeting only individual proteins. Whereas ICI sensitive MCF-7/LCC1 cells undergo increased apoptosis in response to ICI following BCL-W+/-BCL2 co-inhibition, the consequent resensitization of resistant MCF-7/LCC9 and LY2 cells reflects increases in autophagy (LC3 cleavage; p62/SQSTM1 expression) and necrosis but not apoptosis or cell cycle arrest. Thus, de novo sensitive cells and resensitized resistant cells die through different mechanisms. Following BCL-W+BCL2 co-inhibition, suppression of functional autophagy by 3-methyladenine or BECN1 shRNA reduces ICI-induced necrosis but restores the ability of resistant cells to die through apoptosis. These data demonstrate the plasticity of cell fate mechanisms in breast cancer cells in the context of antiestrogen responsiveness. Restoration of ICI sensitivity in resistant cells appears to occur through an increase in autophagy-associated necrosis. BCL-W, BCL2, and BECN1 integrate important functions in determining antiestrogen responsiveness, and the presence of functional autophagy may influence the balance between apoptosis and necrosis.
BCL2 家族成员影响乳腺癌中的细胞命运决定,但 BCL-W(BCL2L2)的作用尚不清楚。我们现在使用三种乳腺癌变体中的分子(siRNA;shRNA)和药理学(YC137)方法,显示抗凋亡 BCL-W 和 BCL2 对雌激素拮抗剂 ICI 182,780(ICI;氟维司群 Faslodex)的反应性的综合作用,MCF-7/LCC1(ICI 敏感),MCF-7/LCC9(ICI 耐药)和 LY2(ICI 耐药)。YC137 抑制 BCL-W 和 BCL2,并恢复耐药细胞对 ICI 的敏感性。BCL-W 和 BCL2 的共同抑制既是必需的,也是充分的,可恢复对 ICI 的敏感性,并从机制上解释了 YC137 的作用。这些数据表明 BCL-W 和 BCL2 之间的信号转导存在功能合作和/或冗余,并表明广泛的 BCL2 家族成员抑制剂将比仅靶向单个蛋白具有更大的治疗价值。虽然 ICI 敏感的 MCF-7/LCC1 细胞在 BCL-W+/-BCL2 共抑制后对 ICI 的反应中经历凋亡增加,但耐药 MCF-7/LCC9 和 LY2 细胞的相应再敏化反映了自噬(LC3 切割;p62/SQSTM1 表达)和坏死的增加,但不是凋亡或细胞周期停滞。因此,新敏感细胞和再敏化耐药细胞通过不同的机制死亡。在 BCL-W+BCL2 共抑制后,用 3-甲基腺嘌呤或 BECN1 shRNA 抑制功能性自噬会降低 ICI 诱导的坏死,但会恢复耐药细胞通过凋亡死亡的能力。这些数据表明在雌激素反应性的背景下,乳腺癌细胞中细胞命运机制具有可塑性。耐药细胞中 ICI 敏感性的恢复似乎是通过增加自噬相关坏死来实现的。BCL-W、BCL2 和 BECN1 在确定雌激素反应性方面整合了重要功能,功能性自噬的存在可能会影响凋亡和坏死之间的平衡。